12/02/2025 11:00
AI Takes Center Stage as the Major Threat to Cybersecurity in 2026

Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/Experian's 2026 Data Breach Industry Forecast Now ...

AFP awarded at NPPA’s 2023 "Best Of Photojournalism Competition"

The NPPA (National Press Photographers Association) Awards have honoured AFP photographer Luis Tato with three prizes in the Science, Science Story and Politics Story categories.

The NPPA (National Press Photographers Association) Awards have honoured AFP photographer Luis Tato with three prizes in the Science, Science Story and Politics Story categories.
12/02/2025 11:32
Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose p...